Obesity is not predictive of overall survival following permanent prostate brachytherapy

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 30, Issue 6, 2007, Pages 588-596

  Merrick, Gregory S ^a,d   Galbreath, Robert W ^a,b   Butler, Wayne M ^a   Wallner, Kent E ^c   Allen, Zachariah A ^a   Adamovich, Edward ^a  

^a WHEELING JESUIT UNIVERSITY   (United States)

^b Ohio University Eastern   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d WHEELING HOSPITAL   (United States)

Author keywords

Brachytherapy; Obesity; Prostate; Survival

Indexed keywords

ADULT; ANDROGEN THERAPY; ARTICLE; BODY MASS; BRACHYTHERAPY; CANCER STAGING; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; COHORT ANALYSIS; DOSIMETRY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GLEASON SCORE; HUMAN; HYPERTENSION; LINEAR REGRESSION ANALYSIS; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; METASTASIS; OBESITY; PROSTATE BIOPSY; PROSTATE CANCER; RISK ASSESSMENT; STATISTICAL ANALYSIS; TOBACCO;

AGED; BRACHYTHERAPY; CAUSE OF DEATH; COHORT STUDIES; COMORBIDITY; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OBESITY; PROSTATIC NEOPLASMS; SURVIVAL RATE;

EID: 37348999210     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e318068b506     Document Type: Article

References (32)

1. Moyad MA. Is obesity a risk factor for prostate cancer and does it even matter? A hypothesis and different perspective. Urology. 2002;59:41-50.
2. Willett WC, Dietz WH, Colditz GA. Guidelines of health weight. N Engl J Med. 1999;341:427-434.
3. Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults. JAMA. 1999;288:1723-1727.
4. Flegal KM. Epidemiologic aspects of overweight and obesity in the United Sates. Physiol Behav. 2005;86:599-602.
5. Yang B, Gan T, Salmen C, et al. Radical perineal prostatectomy for treatment of localized prostate cancer in obese and nonobese patients: a matched control study. Urology. 2006;67:990-995.
6. National Heart, Lung and Blood Institute Expert Panel on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Executive summary of the clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults. J Am Diet Assoc. 1998;98:1177-1191.
7. Hubbard JS, Rohrmann S, Landis PK, et al. Association of prostate cancer risk with insulin, glucose and anthropometry in the Baltimore Longitudinal Study of Aging. Urology. 2004;63:253-258.
8. Stevens J, Jianwen C, Pamuk ER, et al. The effect of age on the association between body mass index and mortality. N Engl J Med. 1998;338:1-7.
9. Freedland SJ, Aronson WJ, Kane CJ, et al. Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital Database Study Group. J Clin Oncol. 2004;22:1-8.
10. Amling CL, Riffenburgh RH, Sun L, et al. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol. 2004;22:1-7.
11. Freedland SJ, Terris MK, Presti JC. Obesity and biochemical outcome following radical prostatectomy for organ confined disease with negative surgical margins. J Urol. 2004;172:520-524.
12. Strom SS, Kamat AM, Gruschkus SK, et al. Influence of obesity on biochemical and clinical failure after external beam radiotherapy for localized prostate cancer. Cancer. 2006;107:631-639.
13. Mallah KN, DiBlasion CJ, Rhee AC, et al. Body mass index is weakly associated with, and not a helpful predictor of disease progression in men with clinically localized prostate carcinoma treated with radical prostatectomy. Cancer. 2005;103:2030-2034.
14. Merrick GS, Butler WM, Waller KE, et al. Influence of body mass index on biochemical outcome after permanent prostate brachytherapy. Urology. 2005;65:95-100.
15. Calle EE, Rodriquez C, Walker K, et al. Overweight, obesity and mortality from cancer in a prospectively studies cohort of US adults. N Engl J Med. 2003;24:1625-1638.
16. Rodriquez C, Patel AV, Calle EE, et al. Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States. Cancer Epidemiol Biomarkers Prev. 2001;10:345-353.
17. Bassett WW, Cooperberg MR, Sadetsky N, et al. Impact of obesity on prostate cancer recurrence after radical prostatectomy: data from CaPSURE. Urology. 2005;66:1060-1065.
18. Ross P, Sadetsky N, DuChane J, et al. The impact of obesity on secondary treatment, overall survival, and disease-specific survival in men with prostate cancer: results from CaPSURE [Abstract 481]. J Urol. 2006.
19. Pasulka PS, Bistriann BR, Benotti PN, et al. The risks of surgery in obese patients. Ann Intern Med. 1985;104:540-546.
20. Rockhill J, Wallner K, Hoffman C, et al. Prostate brachytherapy in obese patients. Brachytherapy. 2002;1:54-60.
21. Luchka K, Shalev S. Pelvic irradiation of the obese patient: a treatment strategy involving megavoltage simulation and intratreatment setup corrections. Med Phys. 1996;23:1897-1902.
22. Merrick GS, Butler WM, Wallner KE, et al. Permanent prostate brachytherapy-induced morbidity in patients with grade II and III obesity. Urology. 2002;60:104-108.
23. Merrick GS, Butler WM. Modified uniform seed loading for prostate brachytherapy: rationale, design and evaluation. Tech Urol. 2000;6:78-84.
24. Merrick GS, Butler WM, Wallner KE, et al. Extracapsular radiation dose distribution following permanent prostate brachytherapy. Am J Clin Oncol. 2003;26:E178-E189.
25. Nath R, Anderson LL, Luxton G, et al. Dosimetry of interstitial brachytherapy sources: recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. Med Phys. 1995;22:209-234.
26. Merrick GS, Wallner KE, Butler WM. Permanent interstitial brachytherapy for the management of carcinoma of the prostate gland. J Urol. 2003;169:1643-1652.
27. Dattoli M, Wallner K, True L, et al. Long-term outcomes after treatment with external beam radiation therapy and palladium 103 for patients with higher risk prostate carcinoma. Cancer. 2003;97:979-983.
28. Potters L, Morganstern C, Calugaru E, et al. Twelve-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol. 2005;173:1562-1566.
29. Stock R, Cesaretti J, Stone N. Disease-specific survival following the brachytherapy management of prostate cancer. Int J Radiat Oncol Biol Phys. 2006;64:810-816.
30. Lee S, Lindquist K, Segal M, et al. Development and validation of a prognostic index for 4-year mortality in older adults. JAMA. 2006;295:801-808.
31. Ahlering TE, Eichel L, Edwards R, et al. Impact of obesity on clinical outcomes in robotic prostatectomy. Urology. 2005;65:740-744.
32. Millender LE, Aubin M, Poulit J, et al. Daily electronic portal imaging for morbidly obese men undergoing radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2004;59:6-10.